Colesevelam and the Gallbladder: New Research Reveals a Surprising Effect

Table of Contents

• Key Points
• Background: Why This Research Matters
• Understanding Colesevelam: A Medicine With Two Jobs
• Understanding GLP-1: The Blood Sugar Hormone
• Why the Gallbladder and Bile Acids Matter
• Study Methods: How the Research Was Conducted
• Key Findings: What the Researchers Discovered
• Clinical Implications: What This Means for Patients
• Limitations: What This Study Could Not Prove
• Recommendations: Advice for Patients and Doctors
• Frequently Asked Questions
• Source Information

Key Points

• A single dose of colesevelam did not affect post-meal GLP-1 levels in this acute study.
• Colesevelam completely prevented gallbladder refilling after a meal in this trial.
• The gallbladder effect likely results from reduced bile acid reabsorption and lower FGF19.
• This short-term study could not determine if colesevelam increases gallstone risk.
• Patients taking colesevelam with abdominal pain should discuss gallbladder monitoring with their doctor.

Background: Why This Research Matters

Colesevelam belongs to a class of drugs called bile acid sequestrants (bile acid binders). It was originally developed to lower LDL ("bad") cholesterol, and it was later approved to help improve blood sugar control in people with type 2 diabetes. Despite being used in clinical practice for more than two decades, exactly how colesevelam improves glucose metabolism has never been fully explained.

One prominent theory was that colesevelam works by increasing levels of GLP-1 (glucagon-like peptide-1), a natural hormone released by the gut after eating. GLP-1 stimulates the pancreas to release insulin, suppresses the release of glucagon, and slows digestion — all effects that help lower blood sugar. If colesevelam raised GLP-1 levels, that would neatly explain its glucose-lowering benefits. But the evidence for this theory was mixed and mostly indirect.

At the same time, researchers were also interested in colesevelam's effects on the gallbladder, the small pear-shaped organ that stores bile between meals. Because colesevelam works by binding bile acids in the intestine, it is logical to suspect that it affects bile acid physiology and, therefore, gallbladder function. The new study, led by investigators from the University of Copenhagen, was designed to address both questions at once: Does colesevelam acutely raise GLP-1 after a meal? And what does it do to gallbladder motility?

The answers were surprising on both counts.

Understanding Colesevelam: A Medicine With Two Jobs

Colesevelam (sold under brand names such as Welchol) is a large, synthetic molecule that is not absorbed into the bloodstream. Instead, it stays in the digestive tract and binds to bile acids — substances produced by the liver that help digest dietary fats.

Normally, the body recycles bile acids in a process called the enterohepatic circulation. After bile acids are released into the intestine to help digest a meal, most of them are reabsorbed in the lower part of the small intestine (the ileum) and travel back to the liver for reuse. Colesevelam interrupts this recycling loop by binding to bile acids in the gut, preventing their reabsorption. The bound bile acids are then eliminated in the stool. To compensate for the loss, the liver steps up its production of new bile acids — and it uses cholesterol to make them. This is the mechanism by which colesevelam lowers LDL cholesterol levels.

The medicine has two approved uses:

• High cholesterol: It lowers LDL cholesterol in people with primary hyperlipidemia (elevated fats in the blood), often as an add-on to statin therapy.
• Type 2 diabetes: It improves blood sugar control in adults with type 2 diabetes, used alongside diet and exercise.

Because colesevelam stays in the gut, its side effects are mostly digestive. The most common include constipation, bloating, nausea, and indigestion. It can also interfere with the absorption of fat-soluble vitamins (A, D, E, and K) and some other medications, which is why doctors typically advise taking other drugs at least a few hours before or after colesevelam.

Given how colesevelam works — by starving the body of reabsorbed bile acids — it is reasonable to expect that it would influence any process that depends on bile acid signaling. That includes GLP-1 secretion and gallbladder behavior. Until this study, however, the direct connection had not been conclusively tested in a controlled human experiment.

Understanding GLP-1: The Blood Sugar Hormone

GLP-1 is an incretin hormone — a hormone produced by the gut that amplifies insulin secretion in response to food intake. It is released from specialized cells called L-cells, which line the lower intestine, in response to the presence of nutrients (especially carbohydrates and fats).

Once released into the bloodstream, GLP-1 acts on multiple organs:

• It tells the pancreas to release more insulin, lowering blood sugar.
• It suppresses the release of glucagon, a hormone that raises blood sugar.
• It slows the emptying of the stomach, helping to flatten the rise in blood glucose after meals.
• It promotes a feeling of fullness (satiety).

Because of these actions, GLP-1 has become a cornerstone of diabetes treatment. A whole class of highly popular medications — the GLP-1 receptor agonists, such as semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), and dulaglutide (Trulicity) — works by mimicking the actions of natural GLP-1.

Researchers have long wondered whether certain diabetes drugs that are not GLP-1 based might nevertheless work by boosting the body's own GLP-1. Bile acid sequestrants like colesevelam were prime candidates. Bile acids act as signaling molecules in the gut, and some animal experiments suggested that blocking bile acid reabsorption could trigger L-cells to release more GLP-1. If colesevelam did the same in humans, it would explain why the drug helps control blood sugar. The new study was designed to test this hypothesis directly in humans.

Why the Gallbladder and Bile Acids Matter

The gallbladder is a small sac located beneath the liver. Its job is to store and concentrate bile — a yellowish-green fluid produced by the liver that helps digest fats. When you eat, a hormone called cholecystokinin (CCK) is released from the gut, causing the gallbladder to contract and squirt bile into the small intestine.

After emptying, a healthy gallbladder gradually refills with bile over the following hours. This storage-and-release cycle is essential for efficient fat digestion, cholesterol balance, and the overall flow of bile acids through the enterohepatic circulation.

Bile acids are more than just digestive detergents. They are also signaling molecules that activate a receptor called FXR (farnesoid X receptor) in the ileum. When FXR is activated by reabsorbed bile acids, it triggers the release of a hormone called FGF19 (fibroblast growth factor 19) into the bloodstream. FGF19 travels to the liver, where it tells the liver to slow down bile acid production — a classic negative feedback loop.

FGF19 also has another important function: it acts on the gallbladder itself. FGF19 promotes gallbladder relaxation and refilling. This means that when bile acids are absorbed and FGF19 is released, the gallbladder receives a signal to refill with bile. If something interferes with bile acid absorption — as colesevelam does — FGF19 levels could drop, and the gallbladder might lose its refilling signal.

This was exactly the kind of mechanism that the researchers suspected might be at play, and it is why the study measured FGF19 alongside GLP-1 and gallbladder volume. The keywords listed on the paper — colesevelam, GLP-1, gallbladder motility, FGF19, and bile acids — reveal the full scope of what the investigators examined.

Study Methods: How the Research Was Conducted

The study was designed as an acute intervention trial, meaning that it examined the immediate effects of a single dose of colesevelam rather than the effects of weeks or months of treatment. This type of design is ideal for answering mechanistic questions — in this case, "what happens when colesevelam meets a meal?"

Based on the published abstract structure, the study included:

• An objective: to determine whether colesevelam acutely affects postprandial GLP-1 levels and gallbladder motility.
• Methods: participants were studied in a controlled setting, receiving colesevelam and undergoing standardized meal tests, with blood sampling and gallbladder measurements performed at defined time points.
• Results: the findings described in the abstract, which the title summarizes in two key statements.
• A conclusion: interpretation of what the findings mean for the understanding of colesevelam's actions.

In a study of this type, the essential measurements typically include:

• Blood samples drawn at multiple time points to measure plasma levels of GLP-1, FGF19, bile acids, glucose, and insulin.
• Ultrasound imaging of the gallbladder to measure its volume before and after the test meal, which tells researchers whether the gallbladder empties normally and whether it refills as expected.
• A standardized liquid test meal to provoke a consistent postprandial (after-meal) response.

The gold-standard method for studying gallbladder function is gallbladder ultrasonography, a safe, non-invasive technique that allows serial measurements of gallbladder volume over time. By combining ultrasound with blood sampling, researchers can correlate changes in gallbladder behavior with changes in circulating hormones.

This study was published as original research in the European Journal of Endocrinology on 29 March 2024, with peer review oversight from the European Society of Endocrinology. The full methodological details — including the number of participants, their clinical characteristics, the exact dose and timing of colesevelam, and the blood-sampling schedule — are available in the complete article (pages 314–326 of Volume 190).

Key Findings: What the Researchers Discovered

The title of the paper delivers its two central findings in a single sentence: "Colesevelam has no acute effect on postprandial GLP-1 levels but abolishes gallbladder refilling." Each half of that sentence is important.

Finding 1: No acute change in postprandial GLP-1 levels

The first key finding is a "negative" result, but a valuable one. When participants took colesevelam and then ate a meal, their GLP-1 levels rose and fell in the normal pattern — no different from what would be expected without the drug. In other words, colesevelam does not boost GLP-1 in the short term.

This finding challenges the long-held hypothesis that colesevelam improves blood sugar control by raising GLP-1 levels. If the drug's glucose-lowering effect is real — and clinical trials have shown that it is — then it must work through other mechanisms. Possibilities include changes in bile acid signaling, reductions in hepatic glucose production, effects on the gut microbiome, or other pathways that do not involve acute GLP-1 secretion.

It is worth emphasizing that this was an acute study. The question of whether weeks or months of colesevelam treatment could change GLP-1 levels indirectly — for example, by altering the intestinal environment or bile acid pool over time — is a separate question that this study was not designed to answer. What the study clearly shows is that a single dose does not trigger an immediate GLP-1 response.

Finding 2: Gallbladder refilling is completely abolished

The second finding is more striking. After a meal, the gallbladder normally contracts to release bile, and then over the next hours it gradually refills with newly produced bile. In this study, colesevelam completely abolished gallbladder refilling.

The word "abolished" is carefully chosen — it means the effect was not a partial reduction or a delay. The refilling process was entirely prevented. This is a profound alteration of normal digestive physiology, and it has clear connections to the drug's mechanism of action.

Here is the likely chain of events, consistent with the study's focus on FGF19 and bile acids:

1. Normally, after a meal, bile acids are released into the intestine and later reabsorbed in the ileum.
2. Reabsorbed bile acids activate the FXR receptor, which stimulates FGF19 release.
3. FGF19 signals the gallbladder to relax and refill with bile.
4. Colesevelam binds bile acids in the gut, preventing their reabsorption.
5. Without reabsorbed bile acids, FXR activation is reduced, FGF19 release drops, and the gallbladder never receives the signal to refill.

The result: the gallbladder empties once and then stays empty. The implications of this are significant, both for understanding colesevelam's side effects and for the long-term health of the gallbladder in patients taking this medication.

Clinical Implications: What This Means for Patients

For patients taking colesevelam — or considering taking it — this study offers several important takeaways.

First, digestive symptoms have a physiological explanation. Many patients on colesevelam experience bloating, fullness, nausea, or discomfort. The discovery that the gallbladder fails to refill after meals gives doctors a concrete mechanism to explain why patients may feel different after eating while on this drug. A gallbladder that remains collapsed and empty, with bile accumulating in a contracted organ, is not a normal resting state.

Second, the diabetes benefit is not explained by GLP-1. Patients sometimes hear about GLP-1 and assume that every diabetes drug works through that pathway. This study clarifies that colesevelam's acute glucose-lowering effects are not mediated by GLP-1. That is not a problem with the drug — it simply means the mechanism is elsewhere. Research into those alternative mechanisms is ongoing.

Third, there is a theoretical concern about gallstone risk. The gallbladder's job is to store bile. When it fails to refill and bile stagnates — or when bile components become imbalanced — the risk of forming gallstones (hardened deposits in the gallbladder) can increase over time. This study was short-term and did not follow patients long enough to determine whether colesevelam actually increases gallstone risk. However, the finding of abolished refilling is a red flag that warrants further investigation. Patients on long-term colesevelam therapy who develop abdominal pain, nausea, or other symptoms should be evaluated with gallbladder health in mind.

Fourth, combination therapy deserves thought. Some patients take colesevelam alongside other diabetes medications, including GLP-1 receptor agonists. Notably, GLP-1 receptor agonists themselves are known to affect gallbladder motility and have been associated with an increased risk of gallbladder-related events. If a patient is on both a GLP-1 receptor agonist and colesevelam, the combined effects on gallbladder function could, in theory, be additive. This study highlights the importance of considering the whole medication list when assessing digestive risk.

Fifth, the findings strengthen the case for careful prescribing. Colesevelam remains a valuable option for lowering cholesterol and improving blood sugar, particularly because it is not absorbed into the bloodstream and has minimal systemic side effects. But it is not a completely inert drug from the body's perspective — its effects on bile acid handling and gallbladder physiology are real and measurable. Doctors should counsel patients about these effects and monitor for gallbladder-related symptoms.

Limitations: What This Study Could Not Prove

No single study answers every question, and this one has important boundaries that patients and doctors should understand.

Acute design: The study examined the immediate effects of a single dose of colesevelam. It did not assess what happens with daily use over months or years. The human body is remarkably adaptable, and it is possible that chronic colesevelam treatment leads to compensatory changes — in bile acid synthesis, FGF19 signaling, or gallbladder responsiveness — that differ from the acute response. Long-term studies would be needed to know whether the abolished gallbladder refilling persists or normalizes over time.

No long-term outcome data: Because the study was short-term, it could not determine whether colesevelam treatment leads to gallstone formation, cholecystitis (gallbladder inflammation), or gallbladder surgery. The abolished refilling finding raises the question, but it does not answer it.

Limited population: The study was conducted in a specific group of participants, and the abstract text (accessible in full at the journal) provides details on the study population. As with many mechanistic studies, the number of participants is typically small, which is appropriate for detailed physiological measurements but limits the ability to generalize to all patient populations — including those with different ages, ethnicities, or medical conditions.

Single meal test: The postprandial response was assessed following a standardized meal. Real-world eating involves varied meal compositions, sizes, and frequencies, and the gallbladder's behavior may differ under those conditions.

Access limitations: The full article is available through the Oxford University Press journal platform, but at the time of this writing, access requires a subscription or institutional login. Readers who want to examine the specific data, tables, and statistical analyses may need to obtain access through a university library or academic institution.

Despite these limitations, the study's findings are clear on the two central questions it set out to answer: colesevelam does not acutely raise GLP-1 after meals, and it completely abolishes gallbladder refilling. Both findings are robust enough to be reported in the paper's title, which is a strong indication of their confidence in the results.

Recommendations: Advice for Patients and Doctors

For patients currently taking colesevelam, this study should not be a cause for panic, but it should be a reason for informed awareness.

1. Do not stop your medication without speaking to your doctor. Colesevelam provides meaningful benefits for many patients in terms of cholesterol and blood sugar control. The decision to continue, adjust, or stop the medication should be made with a healthcare professional who knows your full medical history.
2. Pay attention to digestive symptoms. If you experience persistent abdominal pain (especially in the upper right side of the abdomen), nausea, vomiting, or bloating while taking colesevelam, mention it to your doctor. These could be signs of gallbladder-related problems.
3. Ask about gallbladder monitoring. If you are on long-term colesevelam therapy and have risk factors for gallstones — such as obesity, rapid weight loss, a family history of gallstones, or female sex (gallstones are more common in women) — consider discussing gallbladder ultrasound with your doctor.
4. Review your complete medication list. If you are also taking a GLP-1 receptor agonist (such as semaglutide, liraglutide, or dulaglutide), ask your doctor whether the combination could affect your gallbladder. Both medications can influence gallbladder motility.
5. For doctors: The findings suggest that patients who report unexplained abdominal pain on colesevelam should not be dismissed lightly. A simple gallbladder ultrasound can clarify whether the drug is causing gallbladder stasis or gallstones, and it may inform treatment decisions.
6. For researchers: This study calls for long-term trials of colesevelam that track gallbladder refilling, bile acid metabolism, FGF19 levels, and clinical outcomes such as gallstone formation. It also invites further investigation into alternative mechanisms — beyond GLP-1 — that explain colesevelam's glucose-lowering effects.

In the meantime, patients and clinicians can feel more confident in understanding what colesevelam does — and does not — do in the body. The drug works, but it is not acting through the GLP-1 pathway in the short term. And its effects on the gallbladder are real and deserve attention.

Frequently Asked Questions

What did this study find about colesevelam and GLP-1 levels after a meal?

In a controlled study, a single dose of colesevelam did not change the normal rise and fall of GLP-1 after a meal. This suggests the drug’s blood sugar benefit is not explained by an acute increase in GLP-1. Other mechanisms may be responsible.

How does colesevelam affect the gallbladder after eating?

The study found that one dose of colesevelam completely prevented the gallbladder from refilling after a meal. Normally, it refills gradually with bile. This effect likely results from reduced bile acid reabsorption and lower FGF19 signaling, which normally triggers gallbladder relaxation and refilling.

Why might colesevelam cause digestive symptoms like bloating or nausea?

This study gives a possible explanation: after a meal, the gallbladder stays empty and does not refill, which is not the normal resting state. This altered gallbladder behavior could contribute to feelings of fullness, nausea, bloating, or discomfort in some people taking colesevelam.

Does colesevelam increase the risk of gallstones?

This short-term study did not follow patients long enough to know if colesevelam causes gallstones. However, completely stopping gallbladder refilling is a concerning finding. If you take colesevelam long-term and have abdominal pain, ask your doctor whether gallbladder monitoring, such as an ultrasound, is appropriate.

Should I stop taking colesevelam because of this study?

Do not stop taking colesevelam without talking to your doctor first. This study provides useful information about how the drug works, but colesevelam offers real benefits for cholesterol and blood sugar. The decision to continue, adjust, or stop your medication should be made with your healthcare provider.

If I take colesevelam and a GLP-1 agonist like semaglutide, is that a problem?

Both colesevelam and GLP-1 receptor agonists can affect gallbladder motility. The study did not test this combination, but it raises the possibility that using both together could have additive effects on the gallbladder. Review your complete medication list with your doctor and discuss any digestive symptoms.

Source Information

This patient-friendly article is based on peer-reviewed research. The original article is:

Original title: "Colesevelam has no acute effect on postprandial GLP-1 levels but abolishes gallbladder refilling"

Authors: Ida M Gether, Emilie Bahne, Henriette H Nerild, Jens F Rehfeld, Bolette Hartmann, Jens J Holst, Tina Vilsbøll, David P Sonne, and Filip K Knop

Journal: European Journal of Endocrinology, Volume 190, Issue 4, April 2024, Pages 314–326

Publication details: Published online 29 March 2024. DOI: 10.1093/ejendo/lvae033

Issue section: Original Research

Keywords: colesevelam, GLP-1, gallbladder motility, FGF19, bile acids

Publisher: Oxford University Press on behalf of the European Society of Endocrinology

This patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and is not a substitute for professional medical advice. Patients with questions about colesevelam or gallbladder health should consult their healthcare provider. The full original article may be accessed through the journal website at academic.oup.com, though institutional access or a subscription may be required for the complete text.